AffiAB® Anti-RUNX1+RUNX2+RUNX3 Antibody [SD0803]

https://www.affiab.com/web/image/product.template/115876/image_1920?unique=a48b62f
(0 review)

CAT# AFG-HB-3465
Size: 100 μL

496.50 496.5 USD 496.50

496.50

For Price Contact info@affigen.com

This combination does not exist.

Terms and Conditions
30-day money-back guarantee
Shipping: 2-3 Business Days

AffiAB® Anti-RUNX1+RUNX2+RUNX3 Antibody [SD0803]

The mammalian Runt-related transcription factor (RUNX) family comprises three members, RUNX1 (also designated AML-1, PEBP2αB, CBFA2) , RUNX2 (also designated AML-3, PEBP2αA, CBFA1, Osf2) and RUNX3 (also designated AML-2, PEBPαC, CBFA3) . RUNX family members are DNA-binding proteins that regulate the expression of genes involved in cellular differentiation and cell cycle progression. RUNX1 is involved in hematopoiesis and is frequently targeted in human leukemia by chromosomal translocations that fuse the DNA-binding domain of RUNX1 to other transcription factors and corepressor molecules. In addition to its role in leukemogenesis, RUNX1 is also involved in sensory neuron diversification. RUNX1 promotes axonal growth, is selectively expressed in neural crest-derived TrkA+ sensory neurons and mediates TrkA transactivation in migratory neural crest cells. RUNX2 is essential for skeletal mineralization in that it stimulates osteoblast differentiation of mesenchymal stem cells, promotes chondrocyte hypertrophy and contributes to endothelial cell migration and vascular invasion of developing bones. Regulating RUNX2 expression may be a useful therapeutic tool for promoting bone formation. Mutations in the C-terminus of RUNX2 are associated with cleidocranial dysplasia syndrome, an autosomal-dominant skeletal dysplasia syndrome that is characterized by widely patent calvarial sutures, clavicular hypoplasia, supernumerary teeth, and short stature. RUNX3 is expressed in cells of hematopoietic origin, including myeloid and B-cell lines and spleen. By playing a role in controlling the growth and differentiation of gastric epithelial cells, RUNX3 is a strong candidate as a gastric cancer tumor suppressor. Specifically, hypermethylation inactivates the gene encoding RUNX3. The detection of hypermethylation at multiple regions within the RUNX3 CpG island may aid in the diagnosis and risk assessment of gastric cancer.

Antibody type

Recombinant Rabbit monoclonal Antibody

Uniprot ID

SwissProt: Q01196 Human; SwissProt: Q13761 Human; SwissProt: Q13950 Human; SwissProt: Q03347 Mouse; SwissProt: Q08775 Mouse; SwissProt: Q64131 Mouse; SwissProt: Q63046 Rat; SwissProt: Q9Z2J9 Rat

Recombinant

YES

Conjugation

Non-conjugated

Host

Rabbit

Isotype

IgG

Clone

SD0803

KO/KD

N/A

Species reactivity

Human

Tested applications

WB, IF-Cell, IF-Tissue, IHC-P, IP, FC

Predicted species reactivity

Mouse, Rat

Immunogen

Synthetic peptide within Human RUNX1 aa 404-453 / 453.

Storage

Store at +4°C after thawing. Aliquot store at -20°C or -80°C. Avoid repeated freeze / thaw cycles.

Form

Liquid

Storage buffer

1*TBS (pH7.4) , 0.05% BSA, 40% Glycerol. Preservative: 0.05% Sodium Azide.

Concentration

1 mg/mL.

Purity

Protein A affinity purified.

Signal pathway

N/A

Recommended dilutions

WB: 1:500-1:2, 000; IF-Cell: 1:50-1:200; IF-Tissue: 1:50-1:200; IHC-P: 1:50-1:200; FC: 1:50-1:100; IP: Use at an assay dependent concentration.

Molecular Weight

49 kDa

Subcellular location

Nucleus, Cytoplasm.

Positive control

Jurkat cell lysates, SHG-44, human tonsil tissue, Jurkat.